[go: up one dir, main page]

NO20026194D0 - Selektive androgen-reseptor-modulatorer og fremgangsmåter for deres identifikasjon, utforming og anvendelse - Google Patents

Selektive androgen-reseptor-modulatorer og fremgangsmåter for deres identifikasjon, utforming og anvendelse

Info

Publication number
NO20026194D0
NO20026194D0 NO20026194A NO20026194A NO20026194D0 NO 20026194 D0 NO20026194 D0 NO 20026194D0 NO 20026194 A NO20026194 A NO 20026194A NO 20026194 A NO20026194 A NO 20026194A NO 20026194 D0 NO20026194 D0 NO 20026194D0
Authority
NO
Norway
Prior art keywords
identification
design
methods
androgen receptor
receptor modulators
Prior art date
Application number
NO20026194A
Other languages
English (en)
Other versions
NO20026194L (no
Inventor
Mark Ernest Salvati
Marco M Gottardis
Jr Stanley R Krystek
Ricardo M Attar
John S Sack
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20026194D0 publication Critical patent/NO20026194D0/no
Publication of NO20026194L publication Critical patent/NO20026194L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20026194A 2000-06-28 2002-12-23 Selektive androgen-reseptor-modulatorer og fremgangsmåter for deres identifikasjon, utforming og anvendelse NO20026194L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21439200P 2000-06-28 2000-06-28
US23351900P 2000-09-19 2000-09-19
US28461701P 2001-04-18 2001-04-18
US28473001P 2001-04-18 2001-04-18
US28443801P 2001-04-18 2001-04-18
PCT/US2001/019665 WO2002000617A2 (en) 2000-06-28 2001-06-20 Selective androgen receptor modulators and methods for their identification, design and use

Publications (2)

Publication Number Publication Date
NO20026194D0 true NO20026194D0 (no) 2002-12-23
NO20026194L NO20026194L (no) 2003-02-26

Family

ID=27539683

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026194A NO20026194L (no) 2000-06-28 2002-12-23 Selektive androgen-reseptor-modulatorer og fremgangsmåter for deres identifikasjon, utforming og anvendelse

Country Status (14)

Country Link
US (2) US6960474B2 (no)
EP (1) EP1299094A2 (no)
JP (1) JP2004509072A (no)
KR (1) KR20030016310A (no)
CN (1) CN1454083A (no)
AU (2) AU8821301A (no)
BR (1) BR0111298A (no)
CA (1) CA2413417A1 (no)
CZ (1) CZ20024214A3 (no)
HU (1) HUP0303172A3 (no)
IL (1) IL152719A0 (no)
MX (1) MXPA02012605A (no)
NO (1) NO20026194L (no)
WO (1) WO2002000617A2 (no)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
IL152719A0 (en) 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
WO2002000653A2 (en) * 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Fused cyclic compounds as modulators of nuclear hormone receptor function
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7622503B2 (en) * 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US20070173546A1 (en) * 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
JP4966477B2 (ja) * 2000-09-19 2012-07-04 ブリストル−マイヤーズ スクイブ カンパニー 核ホルモン・レセプタ機能のモジュレーターである、縮合複素環式スクシンイミド化合物およびその類縁体
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US20040087548A1 (en) * 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
CA2469340A1 (en) 2001-12-06 2003-06-19 Gtx Inc. Treating muscle wasting with selective androgen receptor modulators
JP4434740B2 (ja) 2001-12-19 2010-03-17 ブリストル−マイヤーズ スクイブ カンパニー 核ホルモン受容体機能の調節剤である、縮合ヘテロ環化合物およびその類似体
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
KR20100112659A (ko) 2002-02-07 2010-10-19 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 조절자를 이용한 양성 전립선 과형성증의 치료 방법
KR20040101251A (ko) 2002-02-28 2004-12-02 유니버시티 오브 테네시 리서치 파운데이션 다치환된 선택적 안드로겐 수용체 모듈레이터 및 이를사용하는 방법
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
AU2003217304A1 (en) 2002-02-28 2003-09-16 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
EP1359160A1 (en) * 2002-02-28 2003-11-05 Pfizer Products Inc. Androgen receptor overexpressing skeletal myoblasts
US7772433B2 (en) * 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
HRP20050038A2 (en) 2002-06-17 2005-08-31 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
PL375042A1 (en) 2002-08-12 2005-11-14 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
EP1558232A4 (en) * 2002-10-15 2008-07-02 Gtx Inc TREATMENT OF FAT SUPPORT WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US7332525B2 (en) 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
FR2860793A1 (fr) * 2003-10-14 2005-04-15 Entomed Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations
CN101721402B (zh) * 2003-10-14 2013-03-13 田纳西大学研究基金会 用选择性雄激素受体调节剂治疗骨相关病症
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
WO2005066194A1 (en) 2004-01-07 2005-07-21 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
US7417040B2 (en) * 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7378426B2 (en) * 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
JP5070054B2 (ja) * 2005-08-01 2012-11-07 武田薬品工業株式会社 環状アミン化合物
CA2621983A1 (en) * 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20100004249A1 (en) * 2006-07-11 2010-01-07 Takahiro Matsumoto Bicyclic heterocyclic compound and use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
CN101528214B (zh) 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US7468439B2 (en) * 2006-09-06 2008-12-23 Bristol-Myers Squibb Company Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor function
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20080176255A1 (en) * 2007-01-23 2008-07-24 Edward Sobek Mold detection composition and methods
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2009003077A1 (en) 2007-06-27 2008-12-31 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8466171B2 (en) * 2007-11-01 2013-06-18 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function
EP2489656A1 (en) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
BRPI0907844B8 (pt) * 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US20090280112A1 (en) * 2008-05-05 2009-11-12 The Regents Of The University Of California Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells
EP2334683B1 (en) 2008-08-29 2017-03-22 MSD Italia S.r.l. Saturated bicyclic heterocyclic derivatives as smo antagonists
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US8987319B2 (en) 2010-02-04 2015-03-24 Radius Health, Inc. Selective androgen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
CN102875556B (zh) * 2011-07-12 2016-03-30 天津药明康德新药开发有限公司 (4s)-1-取代-2,5-二氮杂双环[2,2,1]庚烷衍生物及制备方法
HK1208875A1 (en) * 2012-01-12 2016-03-18 耶鲁大学 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
PL2872482T3 (pl) 2012-07-13 2021-03-08 Oncternal Therapeutics, Inc. Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
EA029563B1 (ru) * 2012-07-27 2018-04-30 Арагон Фармасьютикалз, Инк. Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор
AU2013306380A1 (en) 2012-08-23 2015-03-05 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
EP3327144B1 (en) * 2013-02-25 2020-03-25 Novartis AG Novel androgen receptor mutation
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN105640645A (zh) * 2014-11-26 2016-06-08 华东医院 一种多囊卵巢动物模型的建立方法及其应用
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CA2974367A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
SMT202200199T1 (it) 2016-06-22 2022-07-21 Ellipses Pharma Ltd Metodi di trattamento del cancro del seno ar+.
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CA3050309A1 (en) 2017-01-31 2018-08-09 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP3743066A4 (en) 2018-01-26 2021-09-08 Yale University IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE
CA3133929A1 (en) 2019-04-19 2020-10-22 Lin Zhi Crystalline forms and methods of producing crystalline forms of a compound
CR20220353A (es) 2019-12-19 2022-10-20 Arvinas Operations Inc Compuestos y métodos para la degradación dirigida del receptor de andrógenos
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
CN112064141B (zh) * 2020-08-17 2022-11-25 咖法科技(上海)有限公司 一种含茶叶渣的聚乳酸纤维面料制作方法及其面料
US11701332B2 (en) * 2020-11-18 2023-07-18 Bryce Nicholas Day Methods and compositions for treating female sexual interest and arousal disorder
WO2025122895A1 (en) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3343940A (en) 1964-06-12 1967-09-26 Pennsalt Chemicals Corp Process for plant desiccation
US3261845A (en) 1964-07-14 1966-07-19 Dow Chemical Co N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
GB1039020A (en) 1964-09-21 1966-08-17 Biorex Laboratories Ltd Process for the preparation of 5-nitrofurfuraldehyde diacetate
US3428538A (en) 1966-01-13 1969-02-18 Peter Scheiner Method for preparing aziridines by photolysis of triazolines
JPS4916937B1 (no) * 1970-01-21 1974-04-25
US3821232A (en) 1971-12-20 1974-06-28 Petrolite Corp 1,2-dihydro-pyridine-n-phosphonates and thiophosphonates
US4089650A (en) 1971-12-20 1978-05-16 Petrolite Corporation Use of Diels-Alder adducts of dihydro-nitrogen heterocyclic phosphoramidates as corrosion inhibitors
US3998833A (en) 1971-12-20 1976-12-21 Petrolite Corporation Diels-alder adducts of dihydro-nitrogen heterocyclic phosphoramidates
US3923490A (en) 1971-12-20 1975-12-02 Petrolite Corp Use of 1,2-dihydro-pyridine-N-phosphonates and thiophosphonates as microbiocides
US3965264A (en) 1971-12-20 1976-06-22 Petrolite Corporation Process for controlling microbiological organisms in aqueous or petroleum hydrocarbon systems
JPS5013872B2 (no) 1972-03-23 1975-05-23
JPS5032306B2 (no) 1972-11-02 1975-10-20
US3925554A (en) 1972-11-30 1975-12-09 Sumitomo Chemical Co Certain 3,5-dichlorophenyl compound used as a plant fungicide
JPS5339488Y2 (no) 1973-06-12 1978-09-25
US3948933A (en) * 1973-11-01 1976-04-06 Gruppo Lepetit S.P.A. Pyrrolo[1,2-c]imidazolediones
NL7501563A (nl) 1974-02-28 1975-09-01 Merck & Co Inc Werkwijze voor het bereiden van preparaten te- gen het samenpakken van bloedplaatjes.
US3997293A (en) 1974-03-19 1976-12-14 Petrolite Corporation Use of dihydro-nitrogen heterocyclic phosphoramidates as corrosion inhibitors
JPS5417047Y2 (no) * 1974-06-24 1979-07-03
JPS542257Y2 (no) 1974-12-26 1979-01-30
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
JPS5188631A (en) * 1975-01-31 1976-08-03 Hiiryoyosatsukinzai oyobi sonoseizoho
JPS5386035U (no) 1976-12-16 1978-07-15
DE2862100D1 (en) 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
CA1138334A (en) 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
MC1220A1 (fr) * 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
FR2492381A1 (fr) 1980-10-21 1982-04-23 Science Union & Cie Nouveaux acides aza bicyclo alcane carboxyliques substitues leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
JPH0138403Y2 (no) 1981-04-14 1989-11-17
DE3121152A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US4753957A (en) 1981-09-28 1988-06-28 Rohm And Haas Company Substituted 2,4-imidazolidinediones and fungicidal compositions
US4536559A (en) 1983-06-17 1985-08-20 The Boeing Company Thermally stable polyimide polysulfone compositions for composite structures
US5116935A (en) 1987-05-04 1992-05-26 The Boeing Company Polyimide oligomers and blends and method of curing
US5155206A (en) 1987-09-03 1992-10-13 The Boeing Company Crosslinkable polyamideimide oligomers and a method of preparation
US5286811A (en) 1983-09-27 1994-02-15 The Boeing Company Blended polyimide oligomers and method of curing polyimides
US4851495A (en) 1987-02-20 1989-07-25 The Boeing Company Polyetherimide oligomer
US5104967A (en) 1987-09-03 1992-04-14 The Boeing Company Amideimide oligomers and blends
US5516876A (en) 1983-09-27 1996-05-14 The Boeing Company Polyimide oligomers and blends
US5446120A (en) 1985-10-07 1995-08-29 The Boeing Company Polyethersulfone oligomers and blends
US4584364A (en) 1984-02-06 1986-04-22 The Boeing Company Phenolic-capped imide sulfone resins
US5210213A (en) 1983-06-17 1993-05-11 The Boeing Company Dimensional, crosslinkable oligomers
US5367083A (en) 1987-09-03 1994-11-22 The Boeing Company Extended acid halide capping monomers
US5512676A (en) 1987-09-03 1996-04-30 The Boeing Company Extended amideimide hub for multidimensional oligomers
US5693741A (en) 1988-03-15 1997-12-02 The Boeing Company Liquid molding compounds
US5780583A (en) 1991-01-09 1998-07-14 The Boeing Company Reactive polyarylene sulfide oligomers
US5645925A (en) 1988-03-14 1997-07-08 Boeing Company Advanced composite blends
US4507303A (en) 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
DE3382406D1 (de) * 1982-04-08 1991-10-17 Shell Int Research Neue hydantoine, ihre herstellung und verwendung.
DE3227055A1 (de) * 1982-07-20 1984-01-26 Hoechst Ag, 6230 Frankfurt Neue derivate der 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure als zwischenstufe und verfahren zu deren herstellung
US4473393A (en) 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
JPS59118750A (ja) 1982-12-27 1984-07-09 Eisai Co Ltd カルボン酸アミド化合物およびその誘導体
US5112939A (en) 1983-06-17 1992-05-12 The Boeing Company Oligomers having pyrimidinyl end caps
US4739030A (en) * 1983-06-17 1988-04-19 The Boeing Company Difunctional end-cap monomers
US4980481A (en) 1983-06-17 1990-12-25 The Boeing Company End-cap monomers and oligomers
US4476184A (en) 1983-08-09 1984-10-09 The Boeing Company Thermally stable polysulfone compositions for composite structures
US4582886A (en) * 1984-02-27 1986-04-15 General Electric Company Heat curable epoxy resin compositions and epoxy resin curing agents
US4562255A (en) 1984-03-30 1985-12-31 American Home Products Corporation Substituted bi-alicyclic imides
US4533737A (en) 1984-04-02 1985-08-06 General Electric Company Silicon functionalized norbornane carboxyimide and methods for making
JPS60168906U (ja) 1984-04-19 1985-11-09 株式会社フジクラ 微小径孔を有するセラミツク成形体の成形用型枠
GB8411928D0 (en) 1984-05-10 1984-06-13 Robinson Bros Ltd Preparing substituted oxazolines
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4670536A (en) 1985-06-01 1987-06-02 Director-General Of Agency Of Industrial Science And Technology Addition-curable quinoxaline resin oligomer and intermediate material for fiber-reinforced composite
US5610317A (en) 1985-09-05 1997-03-11 The Boeing Company Multiple chemically functional end cap monomers
US4656235A (en) 1985-09-05 1987-04-07 Polytechnic Institute Of New York Siloxane-containing polyimide coatings for electronic devices
US5594089A (en) 1985-09-05 1997-01-14 The Boeing Company Heterocycle or heterocycle sulfone oligomers with multiple chemically functional end caps
US5151487A (en) 1985-09-30 1992-09-29 The Boeing Company Method of preparing a crosslinking oligomer
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US5084472A (en) 1986-11-04 1992-01-28 Roussel Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
JPS6438403U (no) 1987-08-31 1989-03-08
US4892578A (en) 1987-11-06 1990-01-09 Fmc Corporation Phenylmethyl-4,4-dimethyl-3-isoxazolidinone plant regulators
JPH01125381A (ja) 1987-11-11 1989-05-17 Hitachi Ltd 付加反応型イミド系化合物、およびその樹脂組成物、およびその製造方法
US5817744A (en) 1988-03-14 1998-10-06 The Boeing Company Phenylethynyl capped imides
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
DE69022722T2 (de) 1989-03-10 1996-05-02 Endorecherche Inc., Ste-Foy, Quebec Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
FR2649110B1 (fr) 1989-06-29 1994-10-21 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2222633T3 (es) 1989-07-07 2005-02-01 Endorecherche Inc. Terapia combinada para la profilaxis y/o el tratamiento de la hiperplasia prostatica benigna.
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5114612A (en) 1990-04-04 1992-05-19 The United States Of America As Represented By The Department Of Energy Liquid crystal polyester thermosets
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5093500A (en) 1990-10-17 1992-03-03 Shell Oil Company Spirodilactam bisimides
CA2095633C (en) * 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
HUT62296A (en) 1990-12-18 1993-04-28 Sandoz Ag Herbicidal composition comprising hydantoin derivative as active ingredient and process for producing the active ingredient
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
CA2143937A1 (en) * 1992-09-10 1994-03-17 Matthias Schafer Bicyclic imides as herbicides
JP3252486B2 (ja) 1992-09-30 2002-02-04 いすゞ自動車株式会社 セラミックスの成形方法
JPH06235309A (ja) * 1992-12-16 1994-08-23 Mitsubishi Motors Corp 内燃機関用動弁装置
IL107719A0 (en) 1992-12-21 1994-02-27 Du Pont Imidazolones their manufacture and their use as herbicides
DK0611885T3 (no) 1993-02-17 1997-06-30 New Sulzer Diesel Ag
US5399725A (en) 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
JP3429851B2 (ja) 1993-06-10 2003-07-28 三井化学株式会社 感熱記録材料
US5514571A (en) 1993-08-05 1996-05-07 University Technologies International Inc. Cyclin D1 negative regulatory activity
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5539126A (en) 1994-04-20 1996-07-23 Bristol-Myers Squibb Company Method for preparing homochiral maleimide intermediates, via silylation techniques
GB9411800D0 (en) 1994-06-13 1994-08-03 Sandoz Ltd Organic compounds
US6468981B1 (en) 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
EP0777458B1 (en) 1994-09-14 2000-12-06 Central Sheffield University Hospitals NHS Trust Control of hair growth
DE69531998T2 (de) 1994-12-22 2004-07-22 Ligand Pharmaceuticals, Inc., San Diego Steroidrezeptor-modulator verbindungen und methoden
WO1997021993A2 (en) * 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
WO1997021994A1 (en) 1995-12-15 1997-06-19 Abbott Laboratories Method for simultaneous analysis of cell viability, nucleated red blood cells and white blood cell differential
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP0918774B9 (en) 1996-06-27 2002-04-10 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
US6448443B1 (en) 1996-10-16 2002-09-10 President And Fellows Of Harvard College Synthesis of combinatorial libraries of compounds reminiscent of natural products
DE19643555A1 (de) * 1996-10-24 1998-04-30 Univ Dresden Tech Metallischer Gegenstand mit einer dünnen mehrphasigen Oxidschicht sowie Verfahren zu dessen Herstellung
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US5929146A (en) 1996-12-27 1999-07-27 Minnesota Mining And Manufacturing Company Modifying agents for polyolefins
US6300325B1 (en) 1997-01-23 2001-10-09 Smithkline Beecham Corporation IL-8 receptor antagonists
DK0966447T3 (da) 1997-03-03 2003-06-23 Boehringer Ingelheim Pharma Anvendelige små molekyler til behandling af betændelsessygdomme
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
EP0979407A1 (en) 1997-04-29 2000-02-16 The Salk Institute For Biological Studies Methods for identifying ligands for nuclear hormone receptors
IL134651A0 (en) 1997-08-28 2001-04-30 Janus Pharmaceuticals Inc Pharmaceutical compositions containing an anti-androgen
CA2219867A1 (en) 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US5986055A (en) 1997-11-13 1999-11-16 Curagen Corporation CDK2 interactions
US7101681B1 (en) 1997-11-21 2006-09-05 Amgen, Inc. Nuclear hormone receptor drug screens
EP1042305B1 (en) 1997-12-22 2005-06-08 Bayer Pharmaceuticals Corp. INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
JP2000016004A (ja) 1998-06-26 2000-01-18 Toshio Imanaka 無軸キャスター
WO2000001813A2 (en) 1998-06-30 2000-01-13 The University Of British Columbia Peptide inhibitors of androgen-independent activation of androgen receptor
AU771564B2 (en) 1998-07-17 2004-03-25 University Of Rochester Androgen receptor coactivators
KR20010079778A (ko) 1998-09-09 2001-08-22 이시하라 겐조 제초제로 유용한 융합-벤젠 유도체
AU5723199A (en) 1998-09-15 2000-04-03 Signalgene Inc. Marker at the androgen receptor gene for determining breast cancer susceptibility
EP1117836A2 (en) 1998-09-30 2001-07-25 Millennium Pharmaceuticals, Inc. Expressionanalysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
DE69909947T2 (de) 1998-12-02 2004-02-12 Nippon Paper Industries Co. Ltd. Tintenstrahlaufzeichnungsblatt mit einer Bildschutzschicht
JP2000169474A (ja) 1998-12-07 2000-06-20 Kotobuki Seiyaku Kk イソキヌクリジン誘導体及びその製造方法並びにこれを含有する高コレステロール血症治療剤
US6184249B1 (en) * 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6075053A (en) 1999-02-09 2000-06-13 Bionumerik Pharmaceuticals, Inc. Method of reducing or reversing neuropathy
US6358947B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
GB9911238D0 (en) 1999-05-15 1999-07-14 Zeneca Ltd Therapeutic use
DE60027443D1 (de) * 1999-08-27 2006-05-24 Ligand Pharm Inc Androgenrezeptor-modulatorverbindungen und verfahren
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
WO2001019831A1 (en) * 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
JP2003511467A (ja) * 1999-10-14 2003-03-25 ブリストル−マイヤーズ スクイブ カンパニー アンドロゲンレセプターリガンド結合ドメインの結晶構造
CN1185232C (zh) 1999-10-20 2005-01-19 田边制药株式会社 αLβ2介导细胞粘连抑制剂
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
GB9930839D0 (en) 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0005689D0 (en) 2000-03-09 2000-05-03 Schering Ag Crystal
WO2001085695A1 (en) * 2000-05-11 2001-11-15 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
GB0012291D0 (en) 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
GB0012293D0 (en) 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
IL152719A0 (en) 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
JP2004517606A (ja) 2000-06-28 2004-06-17 ブリストル−マイヤーズ　スクイブ　カンパニー アンドロゲンレセプターモデュレーターの同定のための細胞株および細胞ベースのアッセイ
WO2002000653A2 (en) 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Fused cyclic compounds as modulators of nuclear hormone receptor function
WO2002002112A1 (en) 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and anastrozole for providing an antiandrogenic effect and aromatase inhibition
US20030158160A1 (en) 2000-07-05 2003-08-21 Barrington Furr Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
WO2002002113A1 (en) 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
GB0016426D0 (en) 2000-07-05 2000-08-23 Astrazeneca Ab Pharmaceutical combination
MXPA03001632A (es) 2000-08-24 2004-09-10 Univ Tennessee Res Corp Moduladores receptores de androgeno selectivos y metodos para usar los mismos.
JP4966477B2 (ja) * 2000-09-19 2012-07-04 ブリストル−マイヤーズ スクイブ カンパニー 核ホルモン・レセプタ機能のモジュレーターである、縮合複素環式スクシンイミド化合物およびその類縁体
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物

Also Published As

Publication number Publication date
BR0111298A (pt) 2005-05-10
EP1299094A2 (en) 2003-04-09
WO2002000617A2 (en) 2002-01-03
KR20030016310A (ko) 2003-02-26
HUP0303172A2 (hu) 2003-12-29
IL152719A0 (en) 2003-06-24
US6960474B2 (en) 2005-11-01
AU8821301A (en) 2002-01-08
CN1454083A (zh) 2003-11-05
US20020173445A1 (en) 2002-11-21
HUP0303172A3 (en) 2006-05-29
JP2004509072A (ja) 2004-03-25
CA2413417A1 (en) 2002-01-03
NO20026194L (no) 2003-02-26
MXPA02012605A (es) 2003-05-14
WO2002000617A3 (en) 2003-01-30
US20050256048A1 (en) 2005-11-17
AU2001288213B2 (en) 2005-04-14
CZ20024214A3 (cs) 2003-04-16

Similar Documents

Publication Publication Date Title
NO20026194L (no) Selektive androgen-reseptor-modulatorer og fremgangsmåter for deres identifikasjon, utforming og anvendelse
NO20021449L (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og deres anvendelse
DK1455785T3 (da) Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
NO20030111D0 (no) Kjemokinreseptor-modulatorer, deres fremstilling og anvendelse
NO20023300L (no) Autentiseringssystem, autentiseringsanordning og terminal
DK1315881T3 (da) Metode og system til perforering
DE60139045D1 (de) Kommunikationsvorrichtung und Kommunikationsverfahren
NO20015113D0 (no) Nye forbindelser, deres fremstilling og anvendelse
NO20055135D0 (no) Fenylguinoliner og deres anvendelse som ostrogenreseptormodulatorer
NO20015156L (no) 5-pyridyl-1,3-azolforbindelser, deres fremstilling og anvendelse
NO20030439D0 (no) Sikker programmerbar logisk enhet
DE60107922D1 (de) RFID Kommunikationsverfahren und System
DE60126852D1 (de) Datenkommunikationssystem und Empfangsvorrichtung
DK2474694T3 (da) Sikkerhedsindretning og frigivelsesindretning
DE60333751D1 (de) Kommunikationsverfahren, kommunikationssystem und kommunikationseinrichtung
DE60320785D1 (de) Kommunikationsverfahren, kommunikationssystem und kommunikationseinrichtung
NO20014603L (no) Tienopyrimidinforbindelser, deres fremstilling og anvendelse
NO20025357L (no) Antranylamider og deres anvendelse som legemidler
NO20034364L (no) Sapogenin-derivater, deres syntese og anvendelse samt metoder basert pa deres anvendelse
NO20031838D0 (no) Benzokazinonderivater, deres fremstilling og anvendelse
DK1578727T3 (da) Tetrahydroquinolin-derivater og deres anvendelse som FSH-receptor-modulatorer
NO20001781D0 (no) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
DE60044947D1 (de) Codemultiplex-kommunikationssystem und codemultiplex-kommunikationsgerät
DE60118450D1 (de) Kommunikationsverfahren und Kommunikationsgerät
DE60139736D1 (de) Kommunikationsverfahren und Gerät

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application